Tranzyme begins TZP-102 trial in diabetic patients
TZP-102 is an orally-administered promotility agent used to treat diabetic gastroparesis as it targets the ghrelin receptor, which plays a direct role in the stimulation of GI motility.
BeOne Medicines is set to invest $300m in expanding its manufacturing and research operations at the Princeton West Innovation Campus in Hopewell, New Jersey, US.